Trials / Unknown
UnknownNCT05490264
[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- SmartNuclide Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of \[68Ga\]Ga-NOTA-SNA002 and investigate the uptake of \[68Ga\]Ga-NOTA-SNA002 in patients with solid tumors.
Detailed description
After being informed about the study and potential risks, all patients giving written informed consent will be evaluated to determine eligibility for study entry. Patients will receive an injection of \[68Ga\]Ga-NOTA-SNA002 (1.0-5.0mCi) in Day1 and will undergo PET/CT scanning to determine uptake of \[68Ga\]Ga-NOTA-SNA002 in tumor lesions and reference tissues.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | [68Ga]Ga-NOTA-SNA002 | \[68Ga\]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography |
Timeline
- Start date
- 2022-10-18
- Primary completion
- 2024-06-30
- Completion
- 2024-07-30
- First posted
- 2022-08-05
- Last updated
- 2023-12-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05490264. Inclusion in this directory is not an endorsement.